MANNKIND CORP (MNKD) Stock News
NASDAQ:MNKD - Nasdaq - US56400P7069 - Common Stock - Currency: USD
MNKD Latest News, Press Relases and Analysis
MannKind to Present at Upcoming Investor Conferences
MannKind Expands Executive Leadership Team
Dominic Marasco, RPh, joins the company as President, Endocrine Business Unit, effective January 6, 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif.,...
MannKind Expands Executive Leadership Team
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India...
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
MANNKIND CORPORATION ANNOUNCES EXCHANGE OF CONVERTIBLE NOTES FOR STOCK AND CASH...
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
MannKind Shares Are falling Today: What's Going On?
MannKind Corporation (NASDAQ: MNKD) are trading lower Monday. The company released its six-month results from its Phase 3 INHALE-1 pediatric diabetes trial. Here's what you need to know.
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
MANNKIND ANNOUNCES SIX-MONTH RESULTS FROM PHASE 3 INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING INHALED INSULIN (AFREZZA®) ...
MannKind to Present at 2024 UBS Healthcare Conference
MannKind to Present at 2024 UBS Healthcare Conference...
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
MannKind (MNKD) Q3 2024 Earnings Call Transcript
MNKD earnings call for the period ending September 30, 2024.
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
MANNKIND CORPORATION REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ...
MannKind to Present at 2024 UBS Healthcare Conference
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases ...
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
Mannkind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024 ...
First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of NTM Lung Disease...
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
MORE ADULTS WITH TYPE 1 DIABETES ACHIEVED A1C GOAL (<7%) AFTER SWITCHING FROM MULTIPLE DAILY INSULIN INJECTIONS OR AUTOMATED PUMPS TO INHALED INSULIN...
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment...
マンカインド (MannKind) 、非結核性抗酸菌症（NTM）肺疾患治療用クロファジミン (Clofazimine) 吸入懸濁液の日本における第 3 相臨床試験（ICoN-1）開始に向けたPMDA承認取得を発表
韓国とオーストラリアの保健当局からも承認取得、台湾は2024年第4四半期に承認取得予定米国で初の患者無作為化 コネチカット州ダンバリ, Sept. 18, 2024 (GLOBE NEWSWIRE) --...
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development...
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
MannKind to Present at Upcoming Conferences
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development...
MannKind to Present at Upcoming Conferences
Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
KENT KRESA TO RETIRE FROM MANNKIND’S BOARD OF DIRECTORS; STEVEN B. BINDER TO BE APPOINTED TO THE BOARD...
MannKind (MNKD) Q2 2024 Earnings Call Transcript
MNKD earnings call for the period ending June 30, 2024.